Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW
August 6, 2021
- Results of Guidelines-Related Studies Can Be Used in Public Knowledge-Based Filings for Fertility Treatments: MHLW
August 6, 2021
- Veklury Distribution via Govt Purchase to Continue for Now: MHLW
August 6, 2021
- Council OKs Public Knowledge-Based Filing for New Indication for Fibrinogen
August 6, 2021
- Industry Sees Overhaul of CEA Scheme “Too Early,” Chuikyo Reps Agree
August 5, 2021
- Chuikyo Calls for Balanced Price-Setting for “Specific-Use” Drugs, Sakigake Products
August 5, 2021
- Ofev Faces 10%-Plus Cut in Quarterly Price Review; Veklury Gets Listing but No Copay for Now
August 5, 2021
- Chuikyo to Compile Proposal on SaMD Reimbursement by Year-End
August 5, 2021
- Up to 580,000 Doses of AstraZeneca’s COVID Vaccine to Be Distributed in Tokyo
August 5, 2021
- August Listing OK’ed for Evrysdi, Veklury, Verquvo, 2 CGRP Migraine Meds and More
August 4, 2021
- Trintellix to Face 4.3% Price Cut under CEA Scheme, No Change for Coralan
August 4, 2021
- Delytact Gets 1.43 Million Yen Price Tag
August 4, 2021
- Temodar Label Revised to Erase Caveat for Combo Cancer Therapy
August 4, 2021
- New Pharma Industry Vision to Push Predictability for Investment Recovery: Draft Outline
August 3, 2021
- MHLW’s COVID-19 Guide Adds Chugai’s Cocktail Therapy
August 3, 2021
- Veklury to Join NHI Price List to Enter Normal Distribution Channel; Peak Sales Put at 18 Billion Yen
August 3, 2021
- Lilly’s Selpercatinib Clears Key Panel, in Line for September Approval
August 2, 2021
- Takeda’s Pevonedistat Set to Be 1st Legally Backed Sakigake Drug
August 2, 2021
- AstraZeneca Vaccine OK’ed for Age 40 and Up under Emergency Program
August 2, 2021
- GMP Inspections to Be Conducted Unannounced as Basic Rule: MHLW
July 30, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…